Genetic Mutations and Family History
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Dr. Angela Bradbury is leading a study on access to genetic testing and genetic counseling, including a telehealth option.
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Dr. Christine Iacobuzio-Donahue uses tumor tissue samples to study how pancreatic cancer tumors develop, so she can find ways to stop the disease.
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Dr. Sapna Syngal outlines the GENERATE study, which aims to help families with a risk for pancreatic cancer by providing genetic testing.
A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
Genetics impact your treatment for pancreatic cancer. Dr. Sapna Syngal discusses the recommendation of genetic testing for all pancreatic cancer patients.
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.